当前位置:首页>产品中心>单抗/多抗>HEK293T SARS-CoV-2 Spike (PP) Stable Cell Line|HEK293T SARS-CoV-2刺突(PP)稳定细胞系(靶标:新冠病毒刺突蛋白(PP突变)稳定表达细胞系)

HEK293T SARS-CoV-2 Spike (PP) Stable Cell Line|HEK293T SARS-CoV-2刺突(PP)稳定细胞系(靶标:新冠病毒刺突蛋白(PP突变)稳定表达细胞系)

  • 货号:RB9TVK474818
  • 价格:面议
  • 点击:393

产品介绍

产品参数

宿主种属HEK293T
应用FCM
靶标SARS-CoV-2 Spike (PP)
稳定性和储存Frozen in liquid nitrogen.
登录号P0DTC2
背景信息

Spike glycoprotein (SARS-CoV-2 Spike (PP)) is a ~141 kDa protein. Attaches the virion to the cell membrane by interacting with host receptor, initiating the infection. The major receptor is host ACE2. When S2/S2' has been cleaved, binding to the receptor triggers direct fusion at the cell membrane. When S2/S2' has not been cleaved, binding to the receptor results in internalization of the virus by endocytosis using host TFRC and GRM2 and leading to fusion of the virion membrane with the host endosomal membrane. Alternatively, may use NRP1/NRP2 and integrin as entry receptors.

1. Hoffmann, M. et al. (2020) Cell 181, 271-280.e8. PMID: 32142651
2. Walls, AC. et al. (2020) Cell 181, 281-292.e6. PMID: 32155444
3. Cao, W. et al. (2021) Biophysical journal 120, 1011-1019. PMID: 33607086
4. Takeda, M. (2022) Microbiology and immunology 66, 15-23. PMID: 34561887
5. Wrapp, D. et al. (2020) Science (New York, N.Y.) 367, 1260-1263. PMID: 32075877
6. Ou, X. et al. (2020) Nature communications 11, 1620. PMID: 32221306
7. Wang, J. et al. (2021) Cell discovery 7, 119. PMID: 34903715
8. Wang, X. et al. (2023) Journal of virology 97, e0161122. PMID: 36779763
9. Daly, JL. et al. (2020) Science (New York, N.Y.) 370, 861-865. PMID: 33082294
10. Cantuti-Castelvetri, L. et al. (2020) Science (New York, N.Y.) 370, 856-860. PMID: 33082293
产品特性Growth Properties: Adherent; Selection Marker: Puromycin (1 μg/mL)
种属Viral (SARS-CoV-2)
【仅供科学研究使用】

相关产品:
产品名称 点击数
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 571
Anti-Lebrikizumab Non-Neutralizing Recombinant Antibody |抗来瑞珠单抗非中和重组抗体(靶标:来瑞珠单抗非中和抗体) 538
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 629
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 501
Anti-Lebrikizumab Neutralizing Recombinant Antibody |抗来瑞珠单抗中和重组抗体(靶标:来瑞珠单抗中和抗体) 495
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 488
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 415
Anti-Obinutuzumab Non-Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗非中和重组抗体(靶标:奥滨尤妥珠单抗非中和抗体) 353
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 339
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 400
Anti-Obinutuzumab Neutralizing Recombinant Antibody |抗奥滨尤妥珠单抗中和重组抗体(靶标:奥滨尤妥珠单抗中和抗体) 255
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 296
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 350
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 334
Anti-Natalizumab Non-Neutralizing Recombinant Antibody |抗那他珠单抗非中和重组抗体(靶标:那他珠单抗非中和抗体) 455
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 372
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 536
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 451
Anti-Natalizumab Neutralizing Recombinant Antibody |抗那他珠单抗中和重组抗体(靶标:那他珠单抗中和抗体) 349
Anti-Sarilumab Non-Neutralizing Recombinant Antibody|抗萨瑞鲁单抗非中和重组抗体(靶标:萨瑞鲁单抗非中和抗体) 595
总计 33037 个记录,共 1652 页,当前第 1646 页 | 第一页 上一页 下一页 最末页
在线客服
  • 销售热线:
  • 15898894496(同微信)
  • 我要留言
  • 周一至周五每天9:00-17:00